Journal of General Internal Medicine

, Volume 27, Issue 6, pp 669–676 | Cite as

Cost-Effectiveness of Long-Term Outpatient Buprenorphine-Naloxone Treatment for Opioid Dependence in Primary Care

  • Bruce R. Schackman
  • Jared A. Leff
  • Daniel Polsky
  • Brent A. Moore
  • David A. Fiellin
Original Research



Primary care physicians with appropriate training may prescribe buprenorphine-naloxone (bup/nx) to treat opioid dependence in US office-based settings, where many patients prefer to be treated. Bup/nx is off patent but not available as a generic.


We evaluated the cost-effectiveness of long-term office-based bup/nx treatment for clinically stable opioid-dependent patients compared to no treatment.


A decision analytic model simulated a hypothetical cohort of clinically stable opioid-dependent individuals who have already completed 6 months of office-based bup/nx treatment. Data were from a published cohort study that collected treatment retention, opioid use, and costs for this population, and published quality-of-life weights. Uncertainties in estimated monthly costs and quality-of-life weights were evaluated in probabilistic sensitivity analyses, and the economic value of additional research to reduce these uncertainties was also evaluated.


Bup/nx, provider, and patient costs in 2010 US dollars, quality-adjusted life years (QALYs), and incremental cost-effectiveness (CE) ratios ($/QALY); costs and QALYs are discounted at 3% annually.


In the base case, office-based bup/nx for clinically stable patients has a CE ratio of $35,100/QALY compared to no treatment after 24 months, with 64% probability of being < $100,000/QALY in probabilistic sensitivity analysis. With a 50% bup/nx price reduction the CE ratio is $23,000/QALY with 69% probability of being < $100,000/QALY. Alternative quality-of-life weights result in CE ratios of $138,000/QALY and $90,600/QALY. The value of research to reduce quality-of-life uncertainties for 24-month results is $6,400 per person eligible for treatment at the current bup/nx price and $5,100 per person with a 50% bup/nx price reduction.


Office-based bup/nx for clinically stable patients may be a cost-effective alternative to no treatment at a threshold of $100,000/QALY depending on assumptions about quality-of-life weights. Additional research about quality-of-life benefits and broader health system and societal cost savings of bup/nx therapy is needed.


buprenorphine-naloxone primary health care cost-effectiveness opioid substitution therapy 


  1. 1.
    Results from the 2009 National Survey on Drug Use and Health: Volume 1. Summary of National Findings. Accessed November 10, 2011.
  2. 2.
    National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. Effective medical treatment of opiate addiction. JAMA. 1998;280(22):1936–1943.CrossRefGoogle Scholar
  3. 3.
    Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis. 2006;43(Suppl 4):S173–177.PubMedCrossRefGoogle Scholar
  4. 4.
    Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend. 1995;40(1):17–25.PubMedCrossRefGoogle Scholar
  5. 5.
    Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet. 2003;361(9358):662–668.PubMedCrossRefGoogle Scholar
  6. 6.
    Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 1998;93(4):475–486.PubMedCrossRefGoogle Scholar
  7. 7.
    Mattick RP, Ali R, White JM, O’Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction. 2003;98(4):441–452.PubMedCrossRefGoogle Scholar
  8. 8.
    Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2003(2):CD002207.Google Scholar
  9. 9.
    CSAT Buprenorphine Information Center. Drug Addiction Treatment Act of 2000. Accessed November 10, 2011.
  10. 10.
    Arfken CL, Johanson CE, di Menza S, Schuster CR. Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: national surveys of physicians. J Subst Abuse Treat. 2010;39(2):96–104.PubMedCrossRefGoogle Scholar
  11. 11.
    Clark HW. The State of Buprenorphine Treatment. Paper presented at: Buprenorphine in the Treatment of Opioid Addiction: Reassessment 2010; May 10, 2010; Washington, DC.Google Scholar
  12. 12.
    Evaluation of the Buprenorphine Waiver Program: Buprenorphine Reimbursement and Availability Tracking Study. Accessed November 10, 2011.
  13. 13.
    Schackman BR, Merrill JO, McCarty D, Levi J, Lubinski C. Overcoming policy and financing barriers to integrated buprenorphine and HIV primary care. Clin Infect Dis. 2006;43(Suppl 4):S247–253.PubMedGoogle Scholar
  14. 14.
    Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed November 10, 2011.
  15. 15.
    Murray L, ed. Red book 2010 pharmacy’s fundamental reference. Montvale, NJ: Thomson PDR; 2010.Google Scholar
  16. 16.
    Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med. 2007;1(2):62.PubMedCrossRefGoogle Scholar
  17. 17.
    Clark RE, Samnaliev M, Baxter JD, Leung GY. The Evidence Doesn’t Justify Steps By State Medicaid Programs To Restrict Opioid Addiction Treatment With Buprenorphine. Health Aff (Millwood). 2011;30(8):1425–1433.CrossRefGoogle Scholar
  18. 18.
    Anonymous. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction.Treatment Improvement Protocol (TIP) Series 40. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2004.Google Scholar
  19. 19.
    Pyne JM, Tripathi S, French M, McCollister K, Rapp RC, Booth BM. Longitudinal association of preference-weighted health-related quality of life measures and substance use disorder outcomes. Addiction. 2011;106(3):507–515.PubMedCrossRefGoogle Scholar
  20. 20.
    Nosyk B, Sun H, Guh DP, et al. The quality of eight health status measures were compared for chronic opioid dependence. J Clin Epidemiol. 2010;63(10):1132–1144.PubMedCrossRefGoogle Scholar
  21. 21.
    Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.Google Scholar
  22. 22.
    Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349–356.PubMedCrossRefGoogle Scholar
  23. 23.
    Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn’t it increase at the rate of inflation? Arch Intern Med. 2003;163(14):1637–1641.PubMedCrossRefGoogle Scholar
  24. 24.
    Tan-Torres Edejer T, Baltussen R, Adam T, et al., eds. Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis. Geneva: World Health Organization; 2003.Google Scholar
  25. 25.
    Fiellin DA, Moore BA, Sullivan LE, et al. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008;17(2):116–120.PubMedCrossRefGoogle Scholar
  26. 26.
    Fiellin DA, Pantalon MV, Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365–374.PubMedCrossRefGoogle Scholar
  27. 27.
    Alford DP, Labelle CT, Kretsch N, et al. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425–431.PubMedCrossRefGoogle Scholar
  28. 28.
    Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37(4):426–430.PubMedCrossRefGoogle Scholar
  29. 29.
    Gossop M, Marsden J, Stewart D, Kidd T. The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. Addiction. 2003;98(3):291–303.PubMedCrossRefGoogle Scholar
  30. 30.
    Moore BA, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007;22(4):527–530.PubMedCrossRefGoogle Scholar
  31. 31.
    Jones ES, Moore BA, Sindelar JL, O’Connor PG, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009;99(1–3):132–140.PubMedCrossRefGoogle Scholar
  32. 32.
    U.S. Department of Labor Bureau of Labor Statistics. National Compensation Survey. Accessed November 10, 2011.
  33. 33.
    State of Connecticut Department of Labor, History of minimum wage laws. Accessed November 10, 2011.
  34. 34.
    Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1–171. iii-iv.PubMedGoogle Scholar
  35. 35.
    Stein K, Dyer M, Crabb T, et al. A pilot Internet "value of health" panel: recruitment, participation and compliance. Health Qual Life Outcomes. 2006;4:90.PubMedCrossRefGoogle Scholar
  36. 36.
    Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. J Econ Manage Strategy. 1997;6(1):75–90.CrossRefGoogle Scholar
  37. 37.
    Santell JP. Projecting future drug expenditures–1996. Am J Health Syst Pharm. 1996;53(2):139–150.PubMedGoogle Scholar
  38. 38.
    Polsky D, Glick HA, Yang J, Subramaniam GA, Poole SA, Woody GE. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction. 2010;105(9):1616–1624.PubMedCrossRefGoogle Scholar
  39. 39.
    Woody GE, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300(17):2003–2011.PubMedCrossRefGoogle Scholar
  40. 40.
    The EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199–208.CrossRefGoogle Scholar
  41. 41.
    Brooks R. EuroQol: the current state of play. Health Policy. 1996;37(1):53–72.PubMedCrossRefGoogle Scholar
  42. 42.
    Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43(3):203–220.PubMedCrossRefGoogle Scholar
  43. 43.
    Briggs A, Schulpher M, Claxton K. Decision Modelling for Health Economic Evaluation. Oxford, United Kingdom: Oxford University Press; 2006.Google Scholar
  44. 44.
    The Mental Health Parity and Addiction Equity Act. Accessed November 10, 2011.
  45. 45.
    Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165–178.PubMedCrossRefGoogle Scholar
  46. 46.
    Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction. 2001;96(9):1267–1278.PubMedCrossRefGoogle Scholar
  47. 47.
    Stein MD, Cioe P, Friedmann PD. Buprenorphine retention in primary care. J Gen Intern Med. 2005;20(11):1038–1041.PubMedCrossRefGoogle Scholar
  48. 48.
    Parran TV, Adelman CA, Merkin B, et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010;106(1):56–60.PubMedCrossRefGoogle Scholar
  49. 49.
    U.S. Department of Health & Human Services. Centers for Medicare & Medicaid Services. Accessed November 10, 2011.

Copyright information

© Society of General Internal Medicine 2011

Authors and Affiliations

  • Bruce R. Schackman
    • 1
  • Jared A. Leff
    • 1
  • Daniel Polsky
    • 2
  • Brent A. Moore
    • 3
  • David A. Fiellin
    • 4
  1. 1.Department of Public HealthWeill Cornell Medical CollegeNew YorkUSA
  2. 2.Division of Internal MedicineUniversity of Pennsylvania School of MedicinePhiladelphiaUSA
  3. 3.Department of PsychiatryYale University School of MedicineNew HavenUSA
  4. 4.Department of MedicineYale University School of MedicineNew HavenUSA

Personalised recommendations